The test was cultivated by a team headed by Dr Lee Goldstein, of Brigham and Women's Hospital, Boston.
The laser will scan for deposits of beta-amyloid - the protein found in the brains of Alzheimer's patients.
The procedure has had positive results with a trial using mice.
During the test, a short pulse of infrared light was passed into the eyes of four mice afflicted with Alzheimer's and four normal mice. The test correctly identified which mice suffered from the condition.
Dr. Goldstein and his team hope the test could be used to track the disease at its early stages as well as to update disease progression and cover how patient response to Alzheimer's treatments.
Testing for dementia is not simple and currently can only be correctly determined by looking at a post-mortem brain.
The new test uses quasi-elastic light scattering technology that can identify the earliest stages of amyloid deposits in the lens.
Dr. Goldstein told the International Conference on Alzheimer's Disease and Related Disorders in Madrid: "Amyloid in the lens can be detected using extremely sensitive, non-invasive optical techniques.
He added, "This makes the lens an ideal window for early detection and disease monitoring in Alzheimer's."
The scientists confirm that further study is needed before the test can be publicly available.
